CRANBURY, N.J., July 18, 2017 (GLOBE NEWSWIRE) — Amicus Therapeutics (Nasdaq:FOLD), a global biotechnology company at the forefront of therapies for rare and orphan diseases, today announced the closing of its previously announced offering of common stock. Prior to the closing, the underwriters exercised in full their option to purchase an additional 2,755,102 shares of common stock. As a result, the Company issued a total of 21,122,449 shares in the offering at a price of $12.25 per share.

The gross proceeds from the offering to Amicus are expected to be $258.8 million, before deducting underwriting discounts and commissions and estimated offering expenses payable by Amicus. J.P. Morgan Securities LLC and Goldman Sachs & Co. LLC acted as joint book-running managers and BofA Merrill Lynch and Cowen acted as co-lead managers for the offering.

The Company expects to use the net proceeds of the offering for investment in the U.S. and international commercial infrastructure for migalastat HCl, investment in manufacturing capabilities for ATB200, the continued clinical development of its product candidates, research and development expenditures, clinical and pre-clinical trial expenditures, commercialization expenditures and for other general corporate purposes, which may include working capital, capital expenditures, the funding of in-licensing agreements for product candidates, additional technologies or other forms of intellectual property, the acquisition of assets or businesses that are complementary to the Company’s existing business and general and administrative expenses.

Copies of the prospectus supplement and accompanying base prospectus relating to the offering may be obtained by contacting J.P. Morgan Securities LLC, c/o Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, New York 11717 (telephone number: 866-803-9204), or Goldman Sachs & Co. LLC, by mail, Attn: Prospectus Department, 200 West Street, New York, NY 10282, by facsimile: 212-902-9316, by email: [email protected]; or by telephone: 866-471-2526.